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A B S T R A C T
This study aims to evaluate the diagnostic value of percutaneous core needle biopsy (PCNB) in diagnosing acral
bone tumors. The clinical PCNB data of 341 patients with bone tumors were retrospectively analyzed. The
diagnostic accuracy was calculated according to the lesion components (sclerotic, parenchymatous, or cystic),
benign or malignant character, and whether a soft tissue mass was present. The chi-square test was performed
to assess diagnostic accuracy. The accuracy rate for sclerotic and substantive lesions was high (87.5% and
90.1%, respectively), while that for cystic lesions was the lowest. The accuracy diﬀerence in diagnosing benign
and malignant lesions was signiﬁcant (P < 0.001). The existence of an extraskeletal soft tissue mass signiﬁcantly
aﬀected the diagnostic accuracy (P=0.007). PCNB is a safe, accurate, rapid, and eﬀective screening method in
diagnosing bone tumors; however, the diagnostic accuracy for cystic lesions was poorest. The lesions without a
diagnostic biopsy result were most likely to be benign, and the existence of an extraskeletal soft tissue mass
signiﬁcantly aﬀected diagnostic accuracy; therefore, the correct diagnosis of skeletal system lesions still relies on
the coordinated eﬀorts of clinics, pathology, and imaging.
1. Introduction
Because the clinical manifestations and treatment methods of
patients with bone and soft tissue tumors are diverse, determination
of the best treatment options requires a complete assessment before
starting comprehensive treatment. Therefore, obtaining tissue samples
for histopathological diagnosis is an important step prior to the
treatment of bone and soft tissue tumors. Biopsy plays a critical role,
with the purpose of obtaining tissues for diagnosis in order to reduce
complications, prevent potential tumor spread, and avoid interfering
with future treatments [1].
Currently, open or closed biopsy (needle-aspiration or core needle
biopsy) is used to obtain tissue samples. Inappropriate biopsy fails to
provide a tissue diagnosis, and aﬀects limb salvage and survival rates
[2]. Although open biopsy is considered to be the diagnostic reference
standard, with accuracy as high as 98%, it also has an up to 16% risk of
complications such as bleeding, infection, nerve damage, and tumor
spread [3,4]. Because many malignant tumors required amputation in
the past, biopsy had little signiﬁcance for treatment. With the devel-
opment of limb salvage methods, changes in biopsy techniques, with
reduced complications, especially tissue contamination, have become
very important. Percutaneous and open biopsy had similar diagnostic
accuracy [5], but the complication rate of percutaneous biopsy was as
low as 0–10% [1]. Since the rate of false negatives with needle
aspiration biopsy was high and the diagnostic accuracy was low [6],
it could not be used to assess tissue structures, but could only provide
cytological material, and was not the preferred method for the
diagnosis of bone tumors [1]. Therefore, instead of open biopsy,
percutaneous core needle biopsy (PCNB) was developed, and has
become the most simple and economical method for the diagnosis of
bone and soft tissue tumors, with high diagnostic accuracy and low
complication rates [1,7,8].
This study retrospectively analyzed the clinical PCNB data of 341
patients with bone tumors seen in our department from March 2007 to
March 2015; the positive diagnostic rate and accuracy of PCNB was
determined according to lesion components (sclerotic, parenchyma-
tous, or cystic), benign or malignant character, and whether a soft
tissue mass was present, in order to analyze and evaluate diagnostic
results, and to assess diagnostic value and safety.
2. Materials and methods
2.1. General information
Between March 2007 and March 2015, a total of 341 patients
underwent PCNB in our department for pathological diagnosis; there
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were 179 men and 162 women, with an average age of 46 years 3–84
years). The lesions were located in the femur (126 cases), tibia (80),
humerus (47), radius (29), pelvis (20), ulna (17), and hand-foot-
scapula (22). This study was conducted in accordance with the
declaration of Helsinki. This study was conducted with approval from
the Ethics Committee of Xi’an Jiaotong University. Written informed
consent was obtained from all participants.
2.2. Biopsy procedures
The lesion imaging data, including radiography (Type C arm X-ray
machine from SHIMADZU WHA–200, Japan), computed tomography
(CT) (PHILIPS brilliance-16, Netherland), and magnetic resonance
imaging (MRI) (Siemens 3.0T Magnetom verio, Germany), were care-
fully studied before the biopsy; then, a direct and appropriate puncture
approach was selected, which would avoid damaging the mesooecium,
blood vessels, nerves, and vital organs. A total of 255 patients were
operated on under local anesthesia, 86 received epidural anesthesia, and
42 were operated on under CT guidance, and 74 were operated on under
radiography guidance; based on visual inspection of the samples, the
biopsy specimens were expected to contain tumor tissue, necrotic tumor,
necrotic tissue, or regenerated ﬁber vessels. Usually, three puncture
attempts were able to obtain satisfactory samples; specimens 1–3 cm
long were adequate, but cystic samples were diﬃcult to obtain by
puncture and were sampled repeatedly up to 5–6 times. All lesions,
including coagulated blood, were ﬁxed in 10% formaldehyde solution for
examination.
2.3. Evaluation of PCNB results
The lesions were divided according to imaging features into sclerotic,
parenchymatous, or cystic lesions; sclerotic lesions referred to those with
more than 50% intralesional density equal to or higher than that of
surrounding normal bone tissue. Parenchymatous lesions were those
with more than 50% intralesional tumor component as parenchymatous
soft tissue; cystic lesions referred to those with more than 50%
intralesional component displaying liquid, blood, or air-ﬂuid levels on
CT or MRI. Soft tissue masses were classiﬁed according to their imaging
features for evaluation. The biopsy results were assessed and compared
with the gross specimen pathological results and clinical course of
benign lesions, in order to calculate the positive diagnostic and accuracy
rates of PCNB; complications of PCNB were also recorded.
2.4. Statistical methods
SPSS 17 was used for the chi-square trend test, with P < 0.05
considered as statistically signiﬁcant.
3. Results
The 341 patients underwent 354 punctures; 11 patients were
punctured twice in the same lesion, and 13 were punctured at two
diﬀerent lesions. The most common benign tumors were bone giant cell
tumor (n=55), cartilage blastoma (n=16), and aneurysmal bone cyst
(n=15); the most common malignant tumors were metastatic tumor
(n=58), osteosarcoma (n=35), chondrosarcoma (n=15), and myeloma
(n=15). The ﬁnal diagnostic results are shown in Table 1.
3.1. Positive diagnostic rate and accuracy rate of PCNB
A total 312 cases exhibited yielded PCNB results, and 29 cases had
unclear or no diagnosis (among whom 9 then underwent open biopsy);
the overall positive diagnostic rate was 91.5% (312/341), with accuracy
of 85.6% (292/314). The statistical results are shown in Tables 2–4.
There was no signiﬁcant diﬀerence in the accuracy rates for sclerotic
(87.5%) and parenchymatous lesions (90.1%) (P=0.481), while the
accuracy rate of cystic lesions was the poorest (55%) (P < 0.001). The
positive rates for sclerotic (90.3%) and parenchymatous lesions
(95.6%) showed no statistical diﬀerence, while the diﬀerences in
positive rates of sclerotic/parenchymatous and cystic lesions were
statistically signiﬁcant (P < 0.05). The accuracy rates for malignant
(93.3%) and benign lesions (78.7%) showed a signiﬁcant diﬀerence (P
< 0.001), and the positive diagnostic rates for malignant (97.5%) and
benign lesions (86%) were signiﬁcantly diﬀerent (P < 0.001). The
Table 1
Final diagnostic results by PCNB (n=341).
Benign (n=178) n Malignant (n=165) n
Bone giant cell tumor 55 Metastatic tumor 58
Chondroblastoma 16 Osteosarcoma 35
Tuberculosis 7 Myeloma 15
Fibrous dysplasia 13 Lymphoma 8
Osteomyelitis 6 Chondrosarcoma 16
Enchondroma 11 Pleomorphic sarcoma 13
Aneurysmal bone cyst 15 Alveolar sarcoma 3
Eosinophilic granuloma 7 Synovial sarcoma 4
Non-ossifying ﬁbroma 4 Ewing’s sarcoma 6
Hemangioma 4 Liposarcoma 2
Simple bone cyst 11 Fibrosarcoma 1
Desmoid tumor 5 Leiomyosarcoma 1
Bone infarction 4 Paraganglioma 1








Positive rate and accuracy rate of PCNB towards sclerotic, parenchymatous, or cystic lesions.
Classiﬁcation Total PCNB diagnosis Final diagnosis
Positive rate Unclear or no diagnosis Positive rat% Correct diagnosis Accuracy rat%
Sclerotic, lesions 72 65 7 90.3 63 87.5
Parenchymatous, lesions 229 219 10 95.6 207 90.1
Cystic lesions 40 28 12 70 22 55
Total 341 312 29 91.5 292 85.6
Note: Positive diagnostic rate: sclerotic and parenchymatous lesions: X2=2.948, P=0.086; sclerotic and cystic lesions: X2=7.506, P=0.006; parenchymatous and cystic lesions:
X2=29.794, P< 0.001; accuracy rate: sclerotic and parenchymatous lesions: X2=0.496, P=0.481; sclerotic and cystic lesions: X2=14.845, P < 0.001; parenchymatous and cystic lesions:
X2=33.697, P < 0.001.
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diagnostic accuracies of lesions with or without an extraskeletal soft
tissue mass were 93.7% and 83.8% (P=0.007), respectively, and the
positive diagnostic rates were 100% and 89.6%, respectively (P=0.040).
3.2. Open biopsy
Among the 29 cases without a clear PCNB diagnosis, 9 underwent
open biopsy, and 4 were conﬁrmed to be malignant tumors: telangiec-
tatic osteosarcoma, low-grade chondrosarcoma, osteosarcoma, and
osteoblastic osteosarcoma; 25 cases were benign, with the main lesions
being Langerhans cell hyperplasia, simple bone cyst, aneurysmal bone
cyst, fracture healing, degenerative changes, and osteomyelitis/inﬂam-
mation.
3.3. Complications
Among all patients, only 1 experienced a complication: this patient
had a proximal humerus chondroblastoma, and had a hematoma after
PCNB; the main symptoms and pain were controlled with a pressure
dressing. The complication rate for PCNB was 0.29% (1/341).
4. Discussion
Open biopsy has been considered the gold standard of diagnosis,
but compared with needle-aspiration biopsy, it has a high risk of local
contamination, mainly because the incision must be large enough for
hemostasis. For this reason, only cases of unsuccessful percutaneous
biopsy, lack of clear diagnosis by percutaneous biopsy, or results of
percutaneous biopsy inconsistent with clinical or imaging manifesta-
tions would undergo open biopsy [2]. The rate of wound complications
of open biopsy leading to amputation was as high as 4.5% [9]. Although
PCNB also had a risk of iatrogenic spread or implantation of tumor
cells along the needle track [10,11], the incidence was very low, and the
possibility could be ignored [12]. Most researchers did not report the
recurrence of osteosarcoma within the biopsy channel [12–14]. The
complications of PCNB are very low. The procedures strictly abide by
the principles of cancer surgery and anatomical relationships of the
mesooecium, and avoid the impact of biopsy complications on future
surgeries. Anderson et al. [15] discussed the relationship between
percutaneous biopsy and the mesooecium, and suggested that the
relationship between the mesooecium and the surgical approach
should also be recognized in the initial puncture; in biopsies of
sarcoma, 25% of patients might be punctured improperly, requiring a
change in the surgical approach in 10%, with 3% requiring amputation
[16,17]. In this study, the overall complication rate was very low
(0.29%, 1/341); 1 patient had bleeding without nerve damage.
However, this operation must still avoid blood vessels and nerve
bundles to avoid mesooecium contamination.
The components of intratumoral lesions are an important factor
aﬀecting the success rate of percutaneous biopsy; in the past, due to
diﬃculties in sampling sclerotic lesions, the success rate was low. The
use of modern needles made the puncture of sclerotic lesions less
diﬃcult [14]. The modern core needle is a cannula needle; the outer
cannula is a ring driller that can directly break through and sample
sclerotic and tumorous bone. Thus, the tissue structures could be
protected, enabling not only histological diagnosis and tumor grading,
but also immunohistochemistry and molecular analysis, without aﬀect-
ing histological evaluation. In this study, 72 cases were sclerotic
lesions, among which the malignant lesions mainly included chondro-
sarcoma, osteosarcoma, and lymphoma; the benign lesions mainly
included chondroblastoma and ﬁbrous dysplasia, while the infectious
lesions mainly included osteomyelitis and bone tuberculosis. The
cortical bone of the sclerotic lesions could be easily penetrated, with
strong surgical hand-feel, and a larger volume of tumor samples could
be easily obtained; the diagnostic accuracy rate of sclerotic lesions
showed no signiﬁcant diﬀerence from that of parenchymatous lesions.
Percutaneous biopsy for parenchymatous non-sclerotic lesions was
able to obtain suﬃcient specimen to conﬁrm the diagnosis. Uncommon
tumors or uncommon pathological features would make the diagnosis
of bone tumors more diﬃcult, and even a single lesion with mixed
cystic characteristics or sclerotic regions of a bone tumor would make
the diagnosis diﬃcult; therefore, percutaneous biopsy must be per-
formed in diﬀerent areas to avoid misdiagnosis. In this study, 229 cases
were parenchymatous, the main part of the tumor was neither matrix
nor cystic, and the specimens were relatively easily to obtain. Sampling
of a 1–3 cm-long noncystic lesions was required in order to obtain
various features of the tumors, enabling improved diagnostic and
accuracy rates for percutaneous biopsy. For deep tumors, CT/radio-
graphy guidance was simple and safe, and could improve the diagnostic
accuracy of percutaneous biopsy [18,19].
Table 3
Positive rate and accuracy rate of PCNB towards benign and malignant tumors.
Classiﬁcation Total PCNB diagnosis Final diagnosis
Positive rate Unclear or no diagnosis Positive rat% Correct diagnosis Accuracy rat%
Benign lesions 178 153 25 86.0 140 78.7
Malignant lesions 163 159 4 97.5 152 93.3
Sum 341 312 29 91.5 292 85.6
Note: Benign and malignant tumors: positive diagnostic rate: X2=14.691, P< 0.001; accuracy rate: X2=14.739, P < 0.001.
Table 4
Positive rate and accuracy rate of PCNB towards tumors with or without extraskeletal soft tissue mass.
Classiﬁcation Total PCNB diagnosis Final diagnosis
Positive rate Unclear or no diagnosis Positive rat% Correct diagnosis Accuracy rat%
With 63 63 0 100 59 93.7
Without 278 249 29 89.6 233 83.8
Sum 341 312 29 91.5 292 85.6
Note: Tumors with or without extraskeletal soft tissue mass: positive diagnostic rate: X2=7.183, P=0.007; accuracy rate: X2=4.232, P=0.040.
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Cystic lesions contain liquid, blood, and necrotic tissue, making it
diﬃcult to obtain adequate pathological specimens; therefore, the
diagnosis might be diﬃcult. Cystic lesions with air-ﬂuid levels on CT
and MRI are a challenge for the selection of open biopsy or PCNB [20];
the solid tissues inside the CT- and MRI-enhanced scanning area
include the diagnostic tissues, and the liquid regions include the
nondiagnostic tissues, making it diﬃcult for PCNB to obtain adequate
core solid tissues for diagnosis. The blood/ﬂuid drawn from lesions
usually did not yield suﬃcient tumor cells for diagnosis. Therefore,
obtaining simple blood or liquid would be considered invalid for
diagnosis, and the accuracy rate would be the lowest (55%) (P < 0.001).
Sixty-three lesions were surrounded by extraskeletal soft tissue
masses. Because the extraskeletal soft tissue mass of malignant bone
tumors also had the characteristics of the tumors [1], the presence or
absence of an extraskeletal soft tissue mass would signiﬁcantly aﬀect
the accuracy and positive rates of the biopsy; the diagnostic accuracy of
benign and cystic tumors lacking extraskeletal components was worse.
This study also found that the diagnostic accuracy for metastatic
tumors was as high as 100%, consistent with other reports [21–23];
the reason for this high rate of accuracy might be due to the
homogeneous characteristics of metastatic tumors, which made it
easier for PCNB to access tumor cells for the diagnosis [21,24].
In this study, the positive diagnostic rate for malignant lesions was
97.5%, while that of benign lesions was low (86%) (P < 0.001). The 29
cases with no clear PCNB diagnosis underwent open biopsy or close
clinical follow-up; among these, 25 cases were benign, and mainly
comprised Langerhans cell hyperplasia, simple bone cyst, aneurysmal
bone cyst, fracture healing, degenerative changes, and osteomyelitis/
inﬂammation. Four cases were conﬁrmed to be malignant tumors, i.e.,
telangiectatic osteosarcoma, low-grade cartilage sarcoma, osteosarco-
ma, and osteoblastic osteosarcoma. We further investigated cases
without a clear diagnosis, and found that a reason for these diagnostic
results was that benign lesions did not yield a clear diagnosis through
puncture biopsy. The case of a malignant tumor without a clear PCNB
diagnosis was rare, mainly because the sampled biopsy specimen was
not typical, or not representative. Although some cases could be benign
or malignant, the tissue classiﬁcation could not be clariﬁed because the
specimens were small. Our ﬁndings suggested that the results with
unclear or no PCNB diagnosis would be more likely to be benign
lesions, and this result could guide our clinical process [25].
With the evolution of biopsy techniques, as well as needle materials,
specimens obtained by PCNB are suﬃcient to be widely accepted by
bone oncologists. Percutaneous biopsy is very eﬀective and accurate,
with low cost, little trauma, and fewer complications; the needle track
is easily resected in extensive or radical surgery [9,17,26–28].
However, we must recognize that there could a certain misdiagnosis
rate. If there are signiﬁcant diﬀerences among clinical, radiological,
and PCNB ﬁndings, open biopsy must be performed to conﬁrm the
diagnosis; it should also be recognized that not all misdiagnoses from
PCNB might be corrected by open biopsy.
An incorrect or absent PCNB diagnosis could easily lead to incorrect
treatment or catastrophic therapeutic consequences, improvement of
the accuracy of PCNB, particularly for malignant tumors, still requires
further study. Currently, computer navigation-guided puncture could
further improve diagnostic accuracy of PCNB for malignant tumors. As
for suspected malignant lesions ( < 1 cm), the diagnostic accuracy rate
of PCNB could be low, and excision biopsy or computer navigation-
guided radiofrequency ablation should be performed.
The purpose of biopsy is to obtain diagnostic tissues; meanwhile, it
should have minimum complications, limit the potential spread of
tumors, and avoid interfering with subsequent treatments [1,6]. PCNB
should be performed prior to open biopsy because of its low contam-
ination risk and cost. In addition, image-guided biopsy could improve
diagnostic accuracy and reduce the incidence of complications.
However, if percutaneous biopsy yields no diagnosis, a small incision
is required for open biopsy. Correct diagnosis requires a combination
of clinical, radiological, and pathological results, and the information
from these three modalities needs to be comprehensively considered in
order to make the correct diagnosis.
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